Literature DB >> 8319728

Renal complications in glycogen storage disease type I.

W C Reitsma-Bierens1.   

Abstract

Deficiency of the enzyme glucose-6-phosphatase is the biochemical defect in glycogen storage disease type I (GSD I). Normally this enzyme is present in the liver, intestine and kidneys. The lack of the enzyme in the kidney makes it obvious that glycogen storage will not be restricted to the liver but that also the kidneys will be involved, possibly resulting in renal damage. Glycogen storage in the kidney is most outspoken present in the proximal tubular cells. In case of insufficient metabolic control, a Fanconi-like syndrome can develop, disappearing with improved therapy. Although renal disease has not been considered a problem in GSD I, recent findings indicate that especially in adult patients chronic renal disease is a common complication. In the past gout nephropathy and renal stones were the complications mentioned. Recently it appears that in a considerable number of patients after a period of 'silent' hyperfiltration, renal damage develops with proteinuria, hypertension and renal dysfunction later on. In biopsies of such patients focal glomerulosclerosis is found.

Entities:  

Mesh:

Year:  1993        PMID: 8319728     DOI: 10.1007/bf02072091

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

2.  Renal sonographic findings of type I glycogen storage disease in infancy and early childhood.

Authors:  Chun-Chen Lin; Jeng-Daw Tsai; Shuan-Pei Lin; Hung-Chang Lee
Journal:  Pediatr Radiol       Date:  2005-05-19

3.  Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.

Authors:  Julie Clar; Blandine Gri; Julien Calderaro; Marie-Christine Birling; Yann Hérault; G Peter A Smit; Gilles Mithieux; Fabienne Rajas
Journal:  Kidney Int       Date:  2014-04-09       Impact factor: 10.612

4.  Metabolic control and renal dysfunction in type I glycogen storage disease.

Authors:  J I Wolfsdorf; L M Laffel; J F Crigler
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

Review 5.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

6.  Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.

Authors:  Patrícia Margarida Serra Carvalho; Nuno José Marques Mendes Silva; Patrícia Glória Dinis Dias; João Filipe Cordeiro Porto; Lèlita Conceição Santos; José Manuel Nascimento Costa
Journal:  J Diabetes Metab Disord       Date:  2013-06-06

7.  Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Gerjan Navis; Vaclav Fidler; Catharina M L van Dael; G Peter A Smit
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-01       Impact factor: 8.237

8.  Pregnancies in glycogen storage disease type Ia.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Martin Schwarz; Kurt Ullrich; David A Weinstein; Martin Merkel; Pieter J J Sauer; G Peter A Smit
Journal:  Am J Obstet Gynecol       Date:  2008-02-01       Impact factor: 8.661

9.  AA Amyloidosis in a patient with glycogen storage disorder and progressive chronic kidney disease.

Authors:  Jonathan Dick; Nicola Kumar; Catherine Horsfield; Satish Jayawardene
Journal:  Clin Kidney J       Date:  2012-11-04

Review 10.  Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature.

Authors:  Na Xu; Xinxin Han; Yun Zhang; Xiaoming Huang; Weiguo Zhu; Min Shen; Wen Zhang; Chen Jialin; Min Wei; Zhengqing Qiu; Xuejun Zeng
Journal:  Arthritis Res Ther       Date:  2022-02-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.